디에이치엑스컴퍼니

031860KOSDAQ상품 종합 도매업

48.5 / 100

Reference Date: 2026-07-24

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum9.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DHX Company operates diverse businesses including bicycle manufacturing, ICT distribution, biomedicine development, and regional specialty product exports, with the ICT division contributing over 90% of sales. Key products include the blood purification device 'Hemapure', AI-based brain diagnostic tool 'Neuroharmony', and immunopain treatment drug 'Afitoxin', while also conducting R&D in biocosmetics based on skin microbiome technology.

Number of Employees

27people

Average Salary

5.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 8.874.0Point

PBR

0.92Industry Average 0.471.0Point

2.0x industry avg (risky)

ROE

-101.78Industry Average -1.663.5Point

61.3x industry avg (excellent)

Debt Ratio

5.79Industry Average 14.606.5Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -63.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (53%)

Current 693Won52-week high 1,06252-week low 265

1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1

Neutral주권매매거래정지기간변경 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-07-15
Negative불성실공시법인지정예고 (공시번복)2026-07-10
Neutral조회공시요구(현저한시황변동)에대한답변(미확정)2026-07-08
Neutral임시주주총회결과2026-07-07